<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03229499</url>
  </required_header>
  <id_info>
    <org_study_id>827486</org_study_id>
    <secondary_id>R01HL134905</secondary_id>
    <nct_id>NCT03229499</nct_id>
  </id_info>
  <brief_title>Pulmonary Hypertension and Anastrozole Trial</brief_title>
  <acronym>PHANTOM</acronym>
  <official_title>Pulmonary Hypertension and Anastrozole Trial (PHANTOM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to determine whether the study drug, anastrozole may
      improve six minute walk distance at six months compared to placebo and to assess safety and
      side effects up to twelve months in pulmonary arterial hypertension (PAH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in changes in distance walked in six minutes between anastrozole and placebo groups</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in distance walked in six minutes between anastrozole and placebo groups</measure>
    <time_frame>3 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in right ventricular function between anastrozole and placebo groups</measure>
    <time_frame>6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in plasma NT-proBNP level between anastrozole and placebo groups</measure>
    <time_frame>3 months, 6months,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in biomarkers between anastrozole and placebo groups</measure>
    <time_frame>3 months, 6months,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in SF36 between anastrozole and placebo groups</measure>
    <time_frame>3 months, 6months,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in emPHasis-10 between anastrozole and placebo groups</measure>
    <time_frame>3 months, 6months,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in actigraphy-measured physical activity between anastrozole and placebo groups</measure>
    <time_frame>3 months, 6months,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in time-to-clinical worsening (TTCW) between anastrozole and placebo groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in bone mineral density between anastrozole and placebo groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in side effects between anastrozole and placebo groups at twelve months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg (1 tablet)taken by mouth once a day for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet taken by mouth once a day for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Anastrozole is an aromatase inhibitor indicated for:
adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer
first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer
treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>matching placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous documentation of mean pulmonary artery pressure &gt; 25 mm Hg with a pulmonary
             capillary wedge pressure (or left ventricular end-diastolic pressure) &lt; 16 mm Hg and
             PVR &gt; 3 WU at any time before study entry.

          -  Diagnosis of PAH which is idiopathic, heritable, drug- or toxin-induced, or associated
             with connective tissue disease, congenital heart disease, portal hypertension, or HIV
             infection and receiving treatment for PAH.

          -  Most recent pulmonary function tests with FEV1/FVC &gt;50% AND either a) total lung
             capacity &gt; 70% predicted or b) total lung capacity between 60% and 70% predicted with
             no more than mild interstitial lung disease on computerized tomography scan of the
             chest.

          -  Ability to perform six minute walk testing without significant limitations in
             musculoskeletal function or coordination.

          -  If female, post-menopausal state, defined as:

               -  &gt; 50 years old and a) have not menstruated during the preceding 12 months or b)
                  have follicle-stimulating hormone (FSH) levels (&gt; 40 IU/L) or

               -  &lt; 50 years and FSH (&gt; 40 IU/L) or

               -  having had a bilateral oophorectomy.

          -  Informed consent.

        Exclusion Criteria:

          -  Age &lt; 18.

          -  Current treatment with estrogen, hormone therapy, or anti-hormone therapy (tamoxifen,
             fulvestrant, etc.)

          -  WHO Class IV functional status.

          -  History of breast cancer.

          -  Clinically significant untreated sleep apnea.

          -  Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency
             or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection
             fraction &lt; 45% on most recent echocardiography (within 1 year).

          -  Initiation of PAH therapy (prostacyclin analogues, endothelin-1 receptor antagonists,
             phosphodiesterase-5 inhibitors, riociguat, selexipag) within three months of
             enrollment; the dose must be stable for at least three months prior to Baseline Visit.
             PAH therapy which is stopped and then restarted or has dose changes which are not
             related to initiation and uptitration will be allowed within 3 months prior to the
             Baseline Visit.

          -  Hospitalized or acutely ill.

          -  Renal failure (creatinine ≥ 2.0).

          -  Hypercalcemia.

          -  Severe osteoporosis:

             o T score ≤ -2.0 OR T score ≤ -2.5 if on bone modifying treatment

          -  Child-Pugh Class C cirrhosis.

          -  Current or recent (&lt; 3 months) chronic heavy alcohol consumption.

          -  Enrollment in a clinical trial or concurrent use of another investigational drug or
             device within 30 days of screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Kawut, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane Pinder</last_name>
    <phone>215-294-9757</phone>
    <email>pinder@mail.med.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiffany Sharkoski, MPH, MBE</last_name>
    <phone>215-746-4186</phone>
    <email>sharkosk@upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Del Rosario, RN</last_name>
      <phone>650-721-2408</phone>
      <email>pdelrosa@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Roham Zamanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado - Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colton Carter</last_name>
      <email>colton.carter@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Todd Bull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blessing Enobun</last_name>
      <email>benobun1@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Mathai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Heuerman, RN</last_name>
      <phone>314-747-8174</phone>
      <email>sheuerman@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Murali Chakinala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ima Samba</last_name>
      <phone>215-294-9758</phone>
      <email>ima.samba@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Di Pinder</last_name>
      <phone>215-294-9757</phone>
      <email>pinder@mail.med.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Kawut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Palmisciano, RN, BSN</last_name>
      <phone>401-444-4961</phone>
      <email>APalmisciano@Lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Corey Ventetuolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Cordell, RN</last_name>
      <phone>615-343-8277</phone>
      <email>shannon.eason@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>Anna Hemnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2017</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>clinical trial</keyword>
  <keyword>anastrozole</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>PAH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

